Boehringer Ingelheim v. Ajanta Pharma: Consent Judgment in 39 Days
Boehringer Ingelheim brought a patent infringement action against Ajanta Pharma in the Delaware District Court over three patents covering empagliflozin (JARDIANCE®) tablets at 10 mg and 25 mg doses. The case resolved by consent judgment in just 39 days, with the court retaining jurisdiction to enforce performance.
Empagliflozin ANDA dispute resolved by consent judgment in six weeks
Boehringer Ingelheim Corporation and Boehringer Ingelheim International GmbH filed suit on 4 August 2023 in the Delaware District Court (Case No. 1:23-cv-00848) against Ajanta Pharma, asserting infringement of three U.S. patents — US9949998B2, US11090323B2, and US10258637B2 — in connection with Ajanta's proposed 10 mg and 25 mg empagliflozin tablets and Boehringer Ingelheim's branded JARDIANCE® tablets. Judge Colm F. Connolly presided.
The case closed on 12 September 2023, just 39 days after filing. The recorded basis of termination is Consent Judgment. The docket order states that the court retains jurisdiction to enforce performance under the Consent Judgment and any related agreement, and that the parties agree the court has personal jurisdiction and venue for any action to enforce performance. The specific substantive terms of the Consent Judgment and any related agreement are not disclosed in the available public record.
A resolution within 39 days is notably swift for a multi-patent pharmaceutical infringement action, suggesting the parties reached agreement on core terms at or near the outset of litigation. What drove the resolution — and whether any related agreement governs Ajanta's market entry — is not disclosed in the available public record.
See Complete Case & Patent Analysis →Filing to Consent Judgment in 39 days
Case resolved in 39 days — significantly faster than the median ANDA patent litigation timeline
US9949998B2, US11090323B2 & US10258637B2 — empagliflozin tablet patents
Any company developing, manufacturing, or planning ANDA filings for empagliflozin tablets — including 10 mg and 25 mg solid oral dosage forms — should treat all three patents asserted in this case as active enforcement risks. Because the consent judgment was entered without any court ruling on validity or claim scope, these patents carry full legal weight and Boehringer Ingelheim has demonstrated both willingness and speed in pursuing infringement actions.
Official order — verbatim text
The consent judgment order focuses on jurisdiction retention rather than substantive patent findings, confirming that the Delaware District Court entered a binding, agreed resolution without ruling on infringement or validity. The court's express confirmation of personal jurisdiction and venue over both parties for enforcement purposes elevates this beyond a standard stipulated dismissal, giving the judgment ongoing procedural force.
Consent judgment: what the agreed resolution means for both parties
What a consent judgment means in patent litigation
A consent judgment is a binding, court-entered judgment reflecting terms agreed by both parties. Unlike a voluntary dismissal, it carries the full weight of a court order, enabling either party to return to court for enforcement without re-litigating jurisdiction or venue. Here, the court expressly retained jurisdiction to enforce performance under the Consent Judgment and any related agreement.
Court-entered, enforceable orderBoehringer Ingelheim secures an enforceable court order
As the plaintiff, Boehringer Ingelheim obtains a court-entered judgment that protects its empagliflozin patents without the cost and uncertainty of full ANDA litigation. The retained jurisdiction clause means Boehringer Ingelheim can seek court enforcement if Ajanta departs from the agreed terms. The specific substantive protections are not disclosed in the available public record.
Enforceable patent protectionAjanta Pharma bound by court order on empagliflozin entry
Ajanta Pharma is subject to a binding court order governing its conduct with respect to the asserted empagliflozin patents. Any deviation from the Consent Judgment or related agreement exposes Ajanta to enforcement proceedings in the Delaware District Court, which has confirmed its personal jurisdiction and venue over the parties. The precise terms constraining Ajanta's commercial conduct are not disclosed in the available public record.
Bound by court orderRapid resolution reinforces JARDIANCE® patent position
A consent judgment reached within 39 days, before any substantive briefing on patent validity or infringement, leaves Boehringer Ingelheim's three empagliflozin patents unchallenged on the merits in this proceeding. Other generic entrants should treat this outcome as a signal that the asserted patents remain legally untested through litigation and continue to carry enforcement risk for the JARDIANCE® franchise.
Patents unchallenged on meritsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Boehringer-Ingelheim | Individual | /Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim Corporation | Company | Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim International, GMBH | Company | Search in Eureka ↗ |
| Defendant | Ajanta Pharma | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Boehringer-IngelheimSearch in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the SGLT2 inhibitor and empagliflozin patent space
Forward-looking patent and innovation intelligence derived from Boehringer Ingelheim's empagliflozin enforcement activity and the broader SGLT2 inhibitor filing landscape.
Boehringer Ingelheim's empagliflozin patent estate depth
Three distinct U.S. patents with sequential application numbers suggest Boehringer Ingelheim has pursued a layered filing strategy for empagliflozin across multiple innovation cycles. Mapping the full portfolio — beyond the three asserted patents — may reveal additional coverage in combination therapies, extended-release formulations, or cardiovascular indication claims that could affect generic entry timelines.
Layered portfolio strategySGLT2 inhibitor patent filing trends post-approval
The SGLT2 inhibitor class — including empagliflozin, dapagliflozin, and canagliflozin — has seen sustained patent filing activity in new indications (heart failure, CKD), combination products, and paediatric formulations. Innovators and generics alike should monitor this filing front to anticipate the next wave of ANDA litigation targets and freedom-to-operate constraints.
Active filing frontierAjanta Pharma's generic pharmaceutical patent activity
As a generic manufacturer navigating a consent judgment on empagliflozin, Ajanta Pharma's own patent filings — including formulation, process, and manufacturing IP — signal where it is building defensive positions. Tracking Ajanta's portfolio can reveal which therapeutic areas and molecules it is prioritising for future ANDA challenges and where it may seek design-around strategies.
Generic challenger IP mapAdjacent innovation opportunities near empagliflozin claims
With Boehringer Ingelheim's core empagliflozin formulation patents remaining unchallenged in this proceeding, white space may exist in novel delivery mechanisms, co-crystal forms, fixed-dose combinations, or SGLT2/GLP-1 receptor agonist combinations not yet claimed in the asserted patents. These areas may offer R&D teams freedom to operate while addressing unmet clinical needs in cardiometabolic disease.
Cardiometabolic white spaceSimilar empagliflozin and SGLT2 inhibitor patent cases in Delaware
Explore related ANDA patent infringement actions involving empagliflozin and SGLT2 inhibitor formulations filed in the Delaware District Court.
What this case signals for the empagliflozin IP landscape
A 39-day consent judgment against a generic challenger reinforces the defensive strength of Boehringer Ingelheim's empagliflozin patent estate.
Three patents asserted — none adjudicated on the merits
US9949998B2, US11090323B2, and US10258637B2 emerged from this proceeding without any court ruling on validity or infringement. Generic manufacturers evaluating JARDIANCE® entry must treat all three as fully enforceable and plan FTO and challenge strategies accordingly.
39-day resolution sets a precedent for rapid ANDA enforcement
The speed of this consent judgment — before any substantive motion practice — suggests Boehringer Ingelheim's litigation posture on empagliflozin is assertive and well-prepared. Companies holding ANDA approvals or planning Paragraph IV certifications against JARDIANCE® patents should anticipate swift enforcement action.
Boehringer-Ingelheim v Ajanta — key questions answered
The case ended by consent judgment, the recorded basis of termination. Filed on 4 August 2023, it closed on 12 September 2023 — just 39 days later. The court retained jurisdiction to enforce performance under the Consent Judgment and any related agreement. No merits ruling on infringement or patent validity was issued.
Boehringer Ingelheim asserted three U.S. patents: US9949998B2 (application US14/918727), US11090323B2 (application US16/288192), and US10258637B2 (application US15/918401). All three relate to empagliflozin, the active ingredient in JARDIANCE® tablets, which Ajanta sought to market in 10 mg and 25 mg doses.
Ajanta Pharma is bound by a court-entered order in respect of the three asserted empagliflozin patents. The Delaware District Court expressly confirmed personal jurisdiction and venue for enforcement proceedings in the event of any breach. The specific commercial terms — including any market entry date or licensing provisions — are not disclosed in the available public record.
No. The consent judgment was entered without any court ruling on the validity or infringement of US9949998B2, US11090323B2, or US10258637B2. All three patents remain legally intact and their claim scope was not adjudicated in this proceeding, meaning they carry full enforcement potential against other generic challengers.
The case closed in 39 days, before any substantive motion practice was recorded on the public docket. This pace is consistent with parties reaching agreement on key terms at or near the outset of litigation, though the specific factors driving early resolution are not disclosed in the available public record.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.